Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check13 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows a 403 Forbidden error screen, replacing the study information with a standard access-denied layout. This makes the record temporarily inaccessible to users.SummaryDifference19%

- Check55 days agoChange DetectedThe NIH grant/contract note was added to the study identifiers, and the page revision tag was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check76 days agoChange DetectedThe study page now shows an error message and a minimal HTML structure, indicating the record is currently unavailable.SummaryDifference18%

- Check91 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates a new site release is in effect, without altering any study content or data on the page.SummaryDifference0.0%

- Check112 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a new version of the page content.SummaryDifference0.0%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.